Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NANOVIRICIDES, INC. (NNVC)

NanoViricides Enters $ At-the-Market Stock Sales Agreement With D. Boral Capital

Neutral Impact 3 of 5 financing Written later

NanoViricides, Inc. entered into an at-the-market sales agreement with D. Boral Capital LLC, allowing it to sell common stock from time to time under an existing shelf registration. The filing does not state a dollar amount or number of shares, and sales are not required to occur; the company pays a 2.0% commission on gross proceeds from any sales, which would add shares outstanding and dilute existing holders.

Key points

  • Agreement dated July 17, 2026, with D. Boral Capital LLC as sales agent
  • Commission of 2.0% of aggregate gross proceeds from each sale
  • Shares sold under Form S-3 (File No. 333-296550), declared effective June 15, 2026
  • Sales may be made on the NYSE American or in privately negotiated transactions with company consent

The filing

CompanyNANOVIRICIDES, INC. (NNVC)
Form8-K, current report
Filed with the SECJul 17, 2026, 4:45 PM ET
Accession number0001104659-26-084668

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.